menu
    • menu
    [{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Locust Walk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locust Walk \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Locust Walk \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"Bohai Biomedical Technology Development Co.","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"ASEP Medical \/ Bohai Biomedical Technology Development Co.","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medical \/ Bohai Biomedical Technology Development Co."},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"RxOMEG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RxOMEG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"ORAPHARMA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA \/ Not Applicable"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Microspheres, Sustained Release","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipelines for Dental and Oral Health

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hyloris Pharmaceuticals

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hyloris Pharmaceuticals

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hyloris Enrolls First Patient in Phase 3 for Proprietary Mouth Rinse for Dental Bleeding

                            Details : Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.

                            Brand Name : Tranexamic Acid Oral Rinse

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 14, 2024

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ORAPHARMA

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Approved

                            Sponsor : Bausch Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Clinical Study Suggests the Use of OraPharma’s ARESTIN® (minocycline HCl) Microspheres, 1mg May Decreas...

                            Details : ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

                            Brand Name : Arestin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2023

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Approved

                            Sponsor : Bausch Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RxOMEG Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            RxOMEG Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

                            Details : Pilocarpine is a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. Also available orally to treat symptoms of dry mouth associated with Sjogren's syndrome and radiother...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ASEP Medical

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            ASEP Medical

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Preclinical

                            Sponsor : Bohai Biomedical Technology Development Co.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility...

                            Details : The agreement permits Bohai Biomedical to conduct a feasibility study using Asep Inc.'s proprietary anti-bacterial peptide as an active ingredient. The peptide will be studied as an agent to mitigate and prevent erosive dental biofilm infections in an or...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Preclinical

                            Sponsor : Bohai Biomedical Technology Development Co.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Locust Walk

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Locust Walk

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brilacidin

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Innovation Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase ...

                            Details : This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 29, 2020

                            Lead Product(s) : Brilacidin

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Innovation Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth